ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Toronto, ON, CAN:

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...

Enrolling
Uveal Melanoma
Drug: Darovasertib

Phase 2

Ideaya Biosciences

Toronto, Ontario, Canada and 24 other locations

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Toronto, Canada and 44 other locations

the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...

Active, not recruiting
Melanoma
Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib
Drug: Encorafenib and Binimetinib

Phase 3

Pierre Fabre
Pierre Fabre

Toronto, Ontario, Canada and 154 other locations

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma...

Enrolling
Mucosal Melanoma
Cutaneous Melanoma
Drug: Nemvaleukin Alfa Intravenous Less Frequent Dosing
Drug: Pembrolizumab

Phase 2

Mural Oncology

Toronto, Ontario, Canada and 43 other locations

To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...

Active, not recruiting
Uveal Melanoma
Biological: IMCgp100
Biological: Pembrolizumab

Phase 2

Immunocore
Immunocore

Toronto, Canada and 55 other locations

Locations recently updated

antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...

Enrolling
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Toronto, Ontario, Canada and 65 other locations

of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...

Active, not recruiting
Melanoma
Biological: Durvalumab
Drug: Ceralasertib

Phase 2

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 65 other locations

Locations recently updated

not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma...

Enrolling
Melanoma
Drug: Nivolumab + Relatlimab
Drug: rHuPH20

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Toronto, Ontario, Canada and 189 other locations

be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on either pembrolizumab o...

Active, not recruiting
Stage III/IV Melanoma
Biological: Pembrolizumab
Biological: tavokinogene telseplasmid

Phase 2

OncoSec Medical

Toronto, Ontario, Canada and 32 other locations

and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...

Active, not recruiting
Melanoma
Other: Placebo
Biological: Nivolumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Toronto, Ontario, Canada and 128 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems